If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML) and wonder what the official prescribing information says. For decades, pharmacovigilance systems have monitored post-market drug safety, and the association between Tysabri and PML represents a well-documented example of a rare but serious adverse event. This page reviews the FDA's prescribing context for Tysabri, including risk factors, monitoring recommendations, and the evidence behind the PML warning.
Building on the general framework, it is essential to examine the specific medical evidence linking Tysabri to PML. Tysabri (natalizumab) is a monoclonal antibody indicated for the treatment of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is prominently displayed in the prescribing information and underscores the gravity of the risk. The clinical presentation of PML is characterized by progressive neurological deficits, including cognitive impairment, motor dysfunction, and visual disturbances. Diagnosis typically involves brain imaging, cerebrospinal fluid analysis for JCV DNA, and biopsy in some cases. The FDA label notes that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
In clinical trials, PML occurred in three patients receiving Tysabri: two among 1869 multiple sclerosis patients treated for a median of 120 weeks, and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases highlight the potential for harm even with relatively short exposure. The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can reactivate latent JCV, leading to PML. The FDA label identifies three key risk factors: "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Anti-JCV antibodies indicate prior exposure to the virus, while longer treatment duration, especially beyond two years, increases cumulative risk. Prior immunosuppressant use further compromises immune surveillance.
The adequacy of warnings regarding Tysabri and PML is a critical consideration. The boxed warning is explicit and requires healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure informed risk-benefit decisions and close monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, the occurrence of PML in clinical trials and post-marketing reports suggests that warnings may not fully prevent harm, particularly in patients with multiple risk factors. Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) has identified numerous adverse events associated with Tysabri, though PML is not explicitly listed in the most frequent reports, which include fatigue, multiple sclerosis relapse, and headache (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). This discrepancy may reflect underreporting or the relative rarity of PML compared to more common symptoms.
Causation-related considerations for affected patients are complex. The FDA label states that PML "has occurred in patients who have received TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), establishing a causal link. However, individual susceptibility varies based on the presence of risk factors. For patients who develop PML, the timeline between exposure and documented harm can range from months to years. In clinical trials, one case occurred after eight doses, while others emerged after longer treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In summary, Tysabri is associated with a well-documented risk of PML, supported by clinical trial data and FDA warnings. The mechanistic link involves JCV reactivation due to immunosuppression, with risk factors including anti-JCV antibodies, treatment duration, and prior immunosuppressant use. While warnings and monitoring programs are in place, the potential for severe harm remains, and patients should be carefully evaluated for risk before and during treatment.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
The FDA has issued a boxed warning for Tysabri (natalizumab) stating that the drug increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The FDA label identifies three key risk factors: the presence of anti-JCV antibodies, duration of therapy (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks, and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.